[go: up one dir, main page]

AR021226A1 - Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica - Google Patents

Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica

Info

Publication number
AR021226A1
AR021226A1 ARP990105207A ARP990105207A AR021226A1 AR 021226 A1 AR021226 A1 AR 021226A1 AR P990105207 A ARP990105207 A AR P990105207A AR P990105207 A ARP990105207 A AR P990105207A AR 021226 A1 AR021226 A1 AR 021226A1
Authority
AR
Argentina
Prior art keywords
rna
chronic hepatitis
interferon alfa
ribavirina
those patients
Prior art date
Application number
ARP990105207A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR021226A1 publication Critical patent/AR021226A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para tratar un paciente que padece de una infeccion por hepatitis C cronica, a los efectos de erradicar el HCV-RNA detectable, quecomprende una terapia combinatoria, la cual emplea una cantidad terapéuticamente efectiva de un derivado deri bavirina de la formula (1) y una cantidadterapéuticamente efectiva de interferon alfa, durante un lapso que varía entre 20 y 80 semanas.
ARP990105207A 1998-10-16 1999-10-14 Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica AR021226A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17405998A 1998-10-16 1998-10-16
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon

Publications (1)

Publication Number Publication Date
AR021226A1 true AR021226A1 (es) 2002-07-03

Family

ID=22634639

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105207A AR021226A1 (es) 1998-10-16 1999-10-14 Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica

Country Status (9)

Country Link
US (1) US6277830B1 (es)
EP (1) EP1121370A1 (es)
KR (1) KR20010080098A (es)
AR (1) AR021226A1 (es)
AU (1) AU1197600A (es)
CO (1) CO5160265A1 (es)
PE (1) PE20001109A1 (es)
WO (1) WO2000023455A1 (es)
ZA (1) ZA200102917B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800616B2 (en) * 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6403564B1 (en) * 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
PL364927A1 (en) * 1999-12-23 2004-12-27 Icn Pharmaceuticals, Inc. Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
JP2003525907A (ja) * 2000-03-09 2003-09-02 シェーリング コーポレイション Ｈｉｖ免疫アジュバント治療
AU2001255495A1 (en) * 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6510314B1 (en) 2000-09-08 2003-01-21 Visteon Global Technologies, Inc. Mixer circuit with output stage for implementation on integrated circuit
AU2002213343A1 (en) * 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP2004534830A (ja) * 2001-06-21 2004-11-18 グラクソ　グループ　リミテッド Ｈｃｖにおけるヌクレオシド化合物
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US20040106785A1 (en) * 2002-07-25 2004-06-03 Micrologix Biotech Inc. Inhibitors of RNA dependent RNA polymerase and uses thereof
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
AU2003296601A1 (en) * 2002-12-10 2004-06-30 F. Hoffmann-La Roche Ag Antiviral nucleoside derivatives
KR20050109918A (ko) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
WO2005013917A2 (en) * 2003-02-28 2005-02-17 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
EA009295B1 (ru) * 2003-05-21 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Соединения в качестве ингибиторов вируса гепатита с
RU2371195C2 (ru) * 2003-08-13 2009-10-27 Говард Дж. Смит Энд Эссошиэйтс Пти Лтд Способ лечения вирусных инфекций
JP2007505071A (ja) * 2003-09-11 2007-03-08 エフ．ホフマン−ラ　ロシュ　アーゲー 結晶多形性ヌクレオシド化合物
EP1668022A1 (en) * 2003-09-11 2006-06-14 F.Hoffmann-La Roche Ag Process for preparing antiviral nucleoside derivatives
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7410979B2 (en) * 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
BRPI0512360A (pt) * 2004-06-23 2008-03-11 Idenix Cayman Ltd derivados de 5-aza-7-deazapurina para o tratamento de flaviviridae
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
ATE512971T1 (de) * 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
CN101203498A (zh) * 2005-05-02 2008-06-18 里格尔药品股份有限公司 包括可代谢部分的杂环抗病毒化合物及其用途
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
JP2010510171A (ja) * 2006-08-21 2010-04-02 ユナイテッド セラピューティクス コーポレーション ウイルス感染症の治療のための併用療法
WO2008067002A2 (en) * 2006-09-11 2008-06-05 Southern Research Institute Azole nucleosides and use as inhibitors of rna and dna varial polymerases
WO2008052722A2 (en) * 2006-11-02 2008-05-08 Heidelberg Pharma Ag Use of ribavirin-conjugates as an anti-viral drug
CL2008001274A1 (es) 2007-05-03 2008-11-03 Intermune Inc Y Array Biopharma Inc Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de.....
US7932277B2 (en) * 2007-05-10 2011-04-26 Intermune, Inc. Peptide inhibitors of hepatitis C virus replication
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
KR20110075019A (ko) 2008-10-15 2011-07-05 인터뮨, 인크. 치료용 항바이러스성 펩티드
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
JP2013505952A (ja) 2009-09-28 2013-02-21 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新しい大環状阻害剤
CA2779244A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
CA2813093A1 (en) 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2013086133A1 (en) 2011-12-06 2013-06-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
GB1482736A (en) 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US4925930A (en) 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
JPH07503851A (ja) * 1992-02-10 1995-04-27 インターフェロン・サイエンシズ、インコーポレイテッド 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP2001503767A (ja) 1996-11-12 2001-03-21 メディヴィル・アクチボラグ ヌクレオシド

Also Published As

Publication number Publication date
AU1197600A (en) 2000-05-08
EP1121370A1 (en) 2001-08-08
CO5160265A1 (es) 2002-05-30
KR20010080098A (ko) 2001-08-22
PE20001109A1 (es) 2000-10-28
US6277830B1 (en) 2001-08-21
ZA200102917B (en) 2002-07-09
WO2000023455A9 (en) 2000-08-24
WO2000023455A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
BR9812484A (pt) Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c
ES2172288T3 (es) Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
HK1052878A1 (zh) 利巴传林-聚乙二醇化干扰素α：丙型肝炎病毒的联合治疗
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
CY1111153T1 (el) Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης
ES2192839T3 (es) Timosina beta 4 oxidada.
BR9915546A (pt) Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica
PT998287E (pt) Utilizacao de levobupivacaina
BR0010082A (pt) Método para melhorar a eficácia de um agente antitumoral
ITBO930205A1 (it) Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
BR0113115A (pt) Tratamento de hepatite c com timosina, interferon e ribavirina
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
AR035300A1 (es) Analogos de nucleosido con base monociclica modificada con carboxamidina
ATE332704T1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Legal Events

Date Code Title Description
FB Suspension of granting procedure